TP53 and neoplasm: These findings suggest that low dose TNF alpha plus ICI may be a viable therapy option in patients with TP53 mutated brain tumors and highlights the principle that synergistic anti-tumor effects of combination therapies might be obtainable with lower doses than those identified in studies with single agent treatments (i.e. below the maximum tolerated dose for single agents).